NICE Continues Tough Approach On Cancer Drugs, Rejects Tarceva, Javlor and Yondelis
This article was originally published in The Pink Sheet Daily
Executive Summary
The British drug costs regulator turns down Roche's Tarceva, Pierre Fabre's Javlor and PharmaMar's Yondelis for use in the NHS in certain indications.
You may also be interested in...
Javlor Falls Short Again At NICE; Even Sole Treatment In Class Faces Cost Hurdle
NICE questions the cost and clinical effectiveness Pierre Fabre’s Javlor for metastatic transitional cell carcinoma in a disappointing final appraisal for the drug.
With Yervoy Approved in Europe, Bristol Activates Reimbursement Talks
BMS hopes that compelling survival data and unmet need will accelerate European patients' access to its novel advanced melanoma drug Yervoy.
With Yervoy Approved in Europe, Bristol Activates Reimbursement Talks
BMS hopes that compelling survival data and unmet need will accelerate European patients' access to its novel advanced melanoma drug Yervoy.